Nasdaq · Healthcare
Inogen Inc (INGN)
As-reported financials and recent SEC filings for Inogen Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$295.3M
Net income
$-22.7M
Net margin
-7.7%
Diluted EPS
$-0.86
ROE
-11.8%
P/E (TTM)
—
Market cap
$187.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $295.3M | $278.8M | $251.6M | $320.5M | $311.7M |
| Gross profit | $100.9M | $97.8M | $62.6M | $96.8M | $130.2M |
| Operating income | $-30.2M | $-42.5M | $-109.4M | $-85.2M | $9.2M |
| Net income | $-22.7M | $-35.9M | $-102.4M | $-83.8M | $-6.3M |
| Diluted EPS | $-0.86 | $-1.52 | $-4.42 | $-3.67 | $-0.28 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-06-12
View on EDGAR →8-K2026-06-11
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →32026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →Go deeper on INGN
Search Inogen Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.